TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2202544
Drug: Diclofenac (75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75‐150 mg daily)
Study: 28635359
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IVPCA)
Study: 21093145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dutasteride (0.5 mg/d) and tamsulosin (0.4 mg/d)
Study: 21093145
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/d)
Study: 17252176
Drug: Early rehabilitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rehabilitation by a rehabilitation specialist, including tailored treatment for post-concussion symptoms (PCS).
Study: 6354604
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Atenolol 100 mg + Indapamide 2.5 mg)
Study: 31923300
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of mini-implants with housings and O-rings (insertion torque ≥ 35 Ncm) or soft relining material (insertion torque < 35 Ncm)
Study: 31923300
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of mini-implants (group B)
Study: 27885399
Drug: Oral selexipag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selexipag (400 μg)
Study: 27885399
Drug: Intravenous selexipag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous selexipag (200 μg)
Study: 26200270
Drug: Folate receptor-positive
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate receptor-positive circulating tumor cells (CTCs) detection using ligand-targeted PCR technique
Study: 22657533
Drug: PZQ syrup
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ syrup
Study: 22657533
Drug: Crushed PZQ
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed PZQ tablet
Study: 18822974
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy for diabetes mellitus with acupuncture at Weiwanxiashu, Feishu, Pishu, Shenshu, Yanglingquan
Study: 11979157
Drug: Light multidisciplinary
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light multidisciplinary treatment
Study: 11790467
Drug: Extensive multidisciplinary
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensive multidisciplinary treatment
Study: 10606107
Drug: Cilostazol plus
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol plus aspirin (C+A)
Study: 10606107
Drug: Ticlopidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine plus aspirin (T+A)
Study: 8941534
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g HMB/day
Study: 8941534
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g HMB/day
Study: 6406458
Drug: bupropion, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion, 50 mg
Study: 6406458
Drug: bupropion, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion, 100 mg
Study: 6406458
Drug: bupropion, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion, 200 mg
Study: 6406458
Drug: bupropion, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion, 100 mg with diazepam, 2.5 and 5 mg
Study: 6406458
Drug: bupropion, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion, 100 mg with alcohol
Study: 6406458
Drug: d‐amphetamine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine, 5 and 10 mg
Study: 6406458
Drug: amitriptyline, 25
Normalized name: Perphenazine-Amitriptyline, 25 mg-2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline, 25 mg
Study: 30666017
Drug: Cold irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold irrigation at 4°C with 17% EDTA and 10 mL of cold saline solution
Study: 30666017
Drug: Cold irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold irrigation at 2.5°C with 17% EDTA and 10 mL of cold saline solution
Study: 30666017
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature irrigation with 17% EDTA and 10 mL of cold saline solution
Study: 29364960
Drug: Empiric TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric TB treatment (n = 82, 49%)
Study: 29364960
Drug: Median time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median time to empiric treatment start
Study: 12072678
Drug: 0.015 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015 mg/kg midazolam
Study: 17599854
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg in 16 oz of decaffeinated coffee)
Study: 4062332
Drug: Anthralin minute
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthralin minute entire skin treatment (AMEST)
Study: 31126331
Drug: sequential-CMAB009 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sequential-CMAB009 therapy
Study: 27303100
Drug: Topiroxostat 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 160 mg daily
Study: 27303100
Drug: Topiroxostat 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 40 mg daily
Study: 26507720
Drug: Riociguat (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (1 mg and 2 mg doses, three times daily for 6 days)
Study: 21138549
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of positive mood color, HAD anxiety, and high TAS score
Study: 11898780
Drug: Vaccine therapy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine therapy for melanoma
Study: 11898780
Drug: Various vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various vaccine strategies
Study: 11898780
Drug: Cancer immunobiology
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer immunobiology underlying vaccine therapy
Study: 9862635
Drug: Extracellular neurofibrillary
Normalized name: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracellular neurofibrillary tangles (eNFTs) stained with antibodies recognizing the 40 carboxy-terminal of Abeta
Study: 9862635
Drug: Intracellular neurofibrillary
Normalized name: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracellular neurofibrillary tangles (iNFTs) immunoreactive with antibodies to the 42 carboxy-terminal epitope
Study: 7545133
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg, twice on the test day)
Study: 972199
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg aerosolized terbutaline sulfate
Study: 21292439
Drug: BTX‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A injection
Study: 31784365
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (Control)
Study: 27290958
Drug: Nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20 μg/kg intravenous bolus)
Study: 27290958
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (comparable volume intravenous bolus)
Study: 22538219
Drug: Topical SAR
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SAR 1118 0.1%
Study: 22538219
Drug: Topical SAR
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SAR 1118 1.0%
Study: 22538219
Drug: Topical SAR
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SAR 1118 5.0%
Study: 22538219
Drug: Topical SAR
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SAR 1118 (all doses)
Study: 17463313
Drug: NeuroThera Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroThera Laser System (active treatment)
Study: 15866309
Drug: N-acetylcysteine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 600 mg daily
Study: 14720008
Drug: Budesonide/formoterol (Symbicort)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (Symbicort) 160/4.5 microg, one inhalation twice daily
Study: 10554443
Drug: Pain management
Normalized name: Olu Pain Management 4%-1% Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain management flow sheet implementation; protocols derived from AHCPR guidelines; specific details on dosage and duration not available.
Study: 9772596
Drug: Fuzheng Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Huoxue Anticancer prescription (FZHXAC)
Study: 2010627
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza B reassortant vaccine
Study: 7046990
Drug: Propranolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80 mg four times daily
Study: 7046990
Drug: Verapamil, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 80 mg four times daily
Study: 27111333
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) with standard stimulation pattern (with environmental sound perception)
Study: 27111333
Drug: Tinnitus Implant
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus Implant (TI) with looped electrical stimulation (without environmental sound perception)
Study: 21956605
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg once daily
Study: 21956605
Drug: Dabigatran 75
Normalized name: dabigatran 75 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 75 mg once daily
Study: 21956605
Drug: Dabigatran 75
Normalized name: dabigatran 75 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 75 mg twice daily
Study: 1988829
Drug: Acyclovir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (30 mg/kg/day for 10 days)
Study: 3298070
Drug: Vidarabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine (15 mg/kg/day for 10 days)
Study: 30576866
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa 0.3 mg/kg/d subcutaneously (SC) for 6 months
Study: 30576866
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa 0.5 mg/kg/d SC for 6 months
Study: 30576866
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa 0.5 mg/kg/d for 6 months, then 1 mg/kg/d 6 days/week for 4.5 years
Study: 30130784
Drug: Topical non‐medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical non‐medicated preparations including pH‐lowered preparations
Study: 24559157
Drug: MEDI-546 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-546 (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg/kg single dose; 0.3, 1.0, or 5.0 mg/kg/week for 4 weeks)
Study: 21766974
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine tablet
Study: 21766974
Drug: No-pill control
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-pill control condition
Study: 15167310
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.625 mg/d
Study: 15167310
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.625 mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d
Study: 15167310
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.45 mg/d
Study: 15167310
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.45 mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d
Study: 15167310
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.45 mg/d + medroxyprogesterone acetate (MPA) 1.5 mg/d
Study: 15167310
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.3 mg/d
Study: 15167310
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.3 mg/d + medroxyprogesterone acetate (MPA) 1.5 mg/d
Study: 9722068
Drug: Glutamine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (1.0 g amino acid/m2/dose swish and swallow four times a day)
Study: 8116534
Drug: High A
Normalized name: High alcohol lager
Approvals — FDA: no, EMA: no, PMDA: no
Description: High A (additional vitamin A in intravenous lipids)
Study: 282081
Drug: active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active therapy
Study: 282081
Drug: no tablets
Normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: no tablets
Study: 30680523
Drug: Aprepitant delayed
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant delayed 1-day administration (125 mg on day 2 and 80 mg on days 3-4)
Study: 30680523
Drug: Routine triple-antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine triple-antiemetic treatment
Study: 28357557
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.25 mg/kg diluted to 10 mL with 0.9% saline)
Study: 28357557
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL of 0.9% saline)
Study: 24667487
Drug: levomilnacipran extended-release
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: levomilnacipran extended-release (ER)
Study: 23320901
Drug: S-1 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 adjuvant therapy (three-week cycle)
Study: 23320901
Drug: S-1 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 adjuvant therapy (six-week cycle)
Study: 21187138
Drug: Individualised herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised herbal prescription
Study: 16890769
Drug: Grass allergen
Normalized name: orchardgrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergen tablet (GRAZAX, ALK‐Abelló, Hørsholm, Denmark) once daily
Study: 9389379
Drug: Acadesine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine (5, 10, 20, 50 mg/kg i.v.)
Study: 7955799
Drug: MK-383 administered
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-383 administered as 1-hour infusion at 0.25 microgram/kg/min
Study: 7955799
Drug: MK-383 administered
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-383 administered as 4-hour infusion at 0.15 microgram/kg/min
Study: 7955799
Drug: Aspirin pretreatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin pretreatment (325 mg)
Study: 3454679
Drug: Memory training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory training combined with oral physostigmine
Study: 27837048
Drug: Rituximab early
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab early drug (week 0/1)
Study: 25421877
Drug: MAP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP regimen (cisplatin 120 mg/m², doxorubicin 75 mg/m², methotrexate 12 g/m² × 2) pre-operatively followed by MAP or MAP with ifosfamide and etoposide post-operatively for patients with ≥10% viable tumour.
Study: 25421877
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy (MAP regimen)
Study: 21917481
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (MT group)
Study: 12351463
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus troglitazone
Study: 12351463
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus metformin vs Insulin plus troglitazone
Study: 2288138
Drug: Fluid intake
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid intake of less than 500 ml beverages per day
Study: 2288138
Drug: Fluid intake
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid intake of more than 2500 ml beverages per day
Study: 31848294
Drug: Higher-dose NaHCO3
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose NaHCO3 (HD-NaHCO3; 0.8 meq/kg of lean body wt per day)
Study: 31848294
Drug: Lower-dose NaHCO3
Normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose NaHCO3 (LD-NaHCO3; 0.5 meq/kg of lean body wt per day)
Study: 23034266
Drug: Oxygen and
Normalized name: Oxygen and/or oxygen compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen and Ozone injections
Study: 23034266
Drug: Pharmacological anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological anti-inflammatory treatment
Study: 1693038
Drug: Allylestrenol (ALE)
Normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allylestrenol (ALE) 50 mg daily for 12 weeks
Study: 1693038
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) 50 mg daily for 12 weeks
Study: 7193005
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bromopride
Study: 31985301
Drug: Halobetasol 0.01%/tazarotene
Normalized name: HALOBETASOL 0.01%/TAZAROTENE 0.045% LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol 0.01%/tazarotene 0.045% lotion (HP/TAZ)
Study: 31205681
Drug: Mild adverse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild adverse events after manual therapy in men
Study: 31205681
Drug: Moderate adverse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate adverse events after manual therapy
Study: 31205681
Drug: No adverse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adverse events after manual therapy
Study: 28044449
Drug: Curves Complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curves Complete 90‐day Challenge (CC, n = 29)
Study: 19559543
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug use behaviors (including methamphetamine and heroin use)
Study: 19559543
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of exchanging sex for money/drugs
Study: 11867507
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of isoflavones per day
Study: 10468094
Drug: Vasoactive therapy
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive therapy
Study: 1352246
Drug: ipsapirone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone 5 mg
Study: 1352246
Drug: ipsapirone (5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (5-30 mg per day)
Study: 6709431
Drug: Isoproterenol aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol aerosol 0.1% inhalation
Study: 25703908
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg IM morphine and 60 μg of sublingual desmopressin melt
Study: 25703908
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg IM morphine
Study: 23625867
Drug: Individualized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized heparin and protamine (HMS group, n=29)
Study: 23625867
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (ACT group, n=24)
Study: 18539869
Drug: Acetaminophen alternated
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alternated with ibuprofen
Study: 16377643
Drug: Didgeridoo lessons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didgeridoo lessons and daily practice at home for four months
Study: 14645637
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (10 ppm on day 1, followed by 5 ppm for six days)
Study: 14645637
Drug: Inhaled oxygen
Normalized name: oxygen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled oxygen placebo
Study: 8509566
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg initial dose, followed by 12.5 mg 2 hours later and continuing with 12.5 mg three times daily)